U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails

The U.K.’s highly controversial Health and Social Care Bill (HSCB), which, among other things, will hand budgetary powers to general practitioners within the National Health Service, is mired in parliament, and the chances of it making it into legislation in a recognizable state are rapidly dwindling. The question for industry is whether, if the Bill falls, it will take the government’s value-based pricing initiative with it.

VBP would, in theory, introduce a range of maximum price thresholds for drugs designed to not only reflect their degree of clinical benefit but also include wider criteria such as...